Global Age-Related Macular Degeneration (AMD) Therapeutics Supply, Demand and Key Producers, 2023-2029
Page: 103
Published Date: 19 Jan 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
This report studies the global Age-Related Macular Degeneration (AMD) Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Age-Related Macular Degeneration (AMD) Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Age-Related Macular Degeneration (AMD) Therapeutics that contribute to its increasing demand across many markets.
The global Age-Related Macular Degeneration (AMD) Therapeutics market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration.
Highlights and key features of the study
Global Age-Related Macular Degeneration (AMD) Therapeutics total market, 2018-2029, (USD Million)
Global Age-Related Macular Degeneration (AMD) Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Age-Related Macular Degeneration (AMD) Therapeutics total market, key domestic companies and share, (USD Million)
Global Age-Related Macular Degeneration (AMD) Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Age-Related Macular Degeneration (AMD) Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Age-Related Macular Degeneration (AMD) Therapeutics total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Age-Related Macular Degeneration (AMD) Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen Inc., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Age-Related Macular Degeneration (AMD) Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Age-Related Macular Degeneration (AMD) Therapeutics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Age-Related Macular Degeneration (AMD) Therapeutics Market, Segmentation by Type
Wet AMD
Dry AMD
Global Age-Related Macular Degeneration (AMD) Therapeutics Market, Segmentation by Application
Hospital
Clinic
Research Institute
Other
Companies Profiled:
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Key Questions Answered
1. How big is the global Age-Related Macular Degeneration (AMD) Therapeutics market?
2. What is the demand of the global Age-Related Macular Degeneration (AMD) Therapeutics market?
3. What is the year over year growth of the global Age-Related Macular Degeneration (AMD) Therapeutics market?
4. What is the total value of the global Age-Related Macular Degeneration (AMD) Therapeutics market?
5. Who are the major players in the global Age-Related Macular Degeneration (AMD) Therapeutics market?
6. What are the growth factors driving the market demand?
Table of Contents
1 Supply Summary
1.1 Age-Related Macular Degeneration (AMD) Therapeutics Introduction
1.2 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Age-Related Macular Degeneration (AMD) Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.3.3 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.3.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.3.5 Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.3.6 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.3.8 India Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Age-Related Macular Degeneration (AMD) Therapeutics Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2.1 World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.2 World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region
2.2.1 World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.4 China Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.5 Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.6 Japan Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.7 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
2.9 India Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029)
3.1 World Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Age-Related Macular Degeneration (AMD) Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Age-Related Macular Degeneration (AMD) Therapeutics in 2022
3.3 Age-Related Macular Degeneration (AMD) Therapeutics Company Evaluation Quadrant
3.4 Age-Related Macular Degeneration (AMD) Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Age-Related Macular Degeneration (AMD) Therapeutics Market: Region Footprint
3.4.2 Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Type Footprint
3.4.3 Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4.1 United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Age-Related Macular Degeneration (AMD) Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Age-Related Macular Degeneration (AMD) Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Age-Related Macular Degeneration (AMD) Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Age-Related Macular Degeneration (AMD) Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Age-Related Macular Degeneration (AMD) Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (2018-2023)
5.1 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Wet AMD
5.2.2 Dry AMD
5.3 Market Segment by Type
5.3.1 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2018-2023)
5.3.2 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2024-2029)
5.3.3 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2018-2029)
6.1 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Research Institute
6.2.4 Other
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2018-2023)
6.3.2 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2024-2029)
6.3.3 World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2018-2029)
7.1 Amgen Inc.
7.1.1 Amgen Inc. Details
7.1.2 Amgen Inc. Major Business
7.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
7.1.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Inc. Recent Developments/Updates
7.1.6 Amgen Inc. Competitive Strengths & Weaknesses
7.2 Bausch Health Companies, Inc.
7.2.1 Bausch Health Companies, Inc. Details
7.2.2 Bausch Health Companies, Inc. Major Business
7.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
7.2.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Bausch Health Companies, Inc. Recent Developments/Updates
7.2.6 Bausch Health Companies, Inc. Competitive Strengths & Weaknesses
7.3 F. Hoffmann-La Roche Ltd.
7.3.1 F. Hoffmann-La Roche Ltd. Details
7.3.2 F. Hoffmann-La Roche Ltd. Major Business
7.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
7.3.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
7.3.6 F. Hoffmann-La Roche Ltd. Competitive Strengths & Weaknesses
7.4 Novartis AG
7.4.1 Novartis AG Details
7.4.2 Novartis AG Major Business
7.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
7.4.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis AG Recent Developments/Updates
7.4.6 Novartis AG Competitive Strengths & Weaknesses
7.5 Regeneron Pharmaceuticals Inc.
7.5.1 Regeneron Pharmaceuticals Inc. Details
7.5.2 Regeneron Pharmaceuticals Inc. Major Business
7.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
7.5.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
7.5.6 Regeneron Pharmaceuticals Inc. Competitive Strengths & Weaknesses
8.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Chain
8.2 Age-Related Macular Degeneration (AMD) Therapeutics Upstream Analysis
8.3 Age-Related Macular Degeneration (AMD) Therapeutics Midstream Analysis
8.4 Age-Related Macular Degeneration (AMD) Therapeutics Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Age-Related Macular Degeneration (AMD) Therapeutics Players in 2022
Table 12. World Age-Related Macular Degeneration (AMD) Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Age-Related Macular Degeneration (AMD) Therapeutics Player
Table 15. Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Type Footprint
Table 16. Age-Related Macular Degeneration (AMD) Therapeutics Market: Company Product Application Footprint
Table 17. Age-Related Macular Degeneration (AMD) Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Age-Related Macular Degeneration (AMD) Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Age-Related Macular Degeneration (AMD) Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Age-Related Macular Degeneration (AMD) Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Age-Related Macular Degeneration (AMD) Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share (2018-2023)
Table 29. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. Amgen Inc. Basic Information, Area Served and Competitors
Table 36. Amgen Inc. Major Business
Table 37. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 38. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Amgen Inc. Recent Developments/Updates
Table 40. Amgen Inc. Competitive Strengths & Weaknesses
Table 41. Bausch Health Companies, Inc. Basic Information, Area Served and Competitors
Table 42. Bausch Health Companies, Inc. Major Business
Table 43. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 44. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Bausch Health Companies, Inc. Recent Developments/Updates
Table 46. Bausch Health Companies, Inc. Competitive Strengths & Weaknesses
Table 47. F. Hoffmann-La Roche Ltd. Basic Information, Area Served and Competitors
Table 48. F. Hoffmann-La Roche Ltd. Major Business
Table 49. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 50. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 52. F. Hoffmann-La Roche Ltd. Competitive Strengths & Weaknesses
Table 53. Novartis AG Basic Information, Area Served and Competitors
Table 54. Novartis AG Major Business
Table 55. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 56. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Novartis AG Recent Developments/Updates
Table 58. Regeneron Pharmaceuticals Inc. Basic Information, Area Served and Competitors
Table 59. Regeneron Pharmaceuticals Inc. Major Business
Table 60. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Services
Table 61. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 62. Global Key Players of Age-Related Macular Degeneration (AMD) Therapeutics Upstream (Raw Materials)
Table 63. Age-Related Macular Degeneration (AMD) Therapeutics Typical Customers
List of Figure
Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Picture
Figure 2. World Age-Related Macular Degeneration (AMD) Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Age-Related Macular Degeneration (AMD) Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Age-Related Macular Degeneration (AMD) Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Age-Related Macular Degeneration (AMD) Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Age-Related Macular Degeneration (AMD) Therapeutics Markets in 2022
Figure 27. United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Age-Related Macular Degeneration (AMD) Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type in 2022
Figure 31. Wet AMD
Figure 32. Dry AMD
Figure 33. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Type (2018-2029)
Figure 34. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Age-Related Macular Degeneration (AMD) Therapeutics Market Size Market Share by Application in 2022
Figure 36. Hospital
Figure 37. Clinic
Figure 38. Research Institute
Figure 39. Other
Figure 40. Age-Related Macular Degeneration (AMD) Therapeutics Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Amgen Inc. Bausch Health Companies, Inc. F. Hoffmann-La Roche Ltd. Novartis AG Regeneron Pharmaceuticals Inc.
Related Reports
11 Jan 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
